Team:Harvard/Judging

From 2011.igem.org

(Difference between revisions)
(Combining Computational Design, High-throughput Synthesis, and Selection)
Line 35: Line 35:
==Human Practices==
==Human Practices==
'''✓''' [http://www.youtube.com/watch?feature=player_embedded&v=eBT8SaBAm80 Interviewed] <html><x>zinc finger researchers</x></html> Dr. Keith Joung and Dr. George Church<br>
'''✓''' [http://www.youtube.com/watch?feature=player_embedded&v=eBT8SaBAm80 Interviewed] <html><x>zinc finger researchers</x></html> Dr. Keith Joung and Dr. George Church<br>
 +
'''✓'''[https://2011.igem.org/Team:Harvard/Technology/Chip_Synthesis#The_Man_Behind_the_Research:_Sriram_Kosuri_on_Chip-Based_DNA_Synthesis Interviewed] chip-based DNA synthesis researcher Dr. Sri Kosuri
'''✓''' [https://2011.igem.org/Team:Harvard/Human_Practices Researched] <html><x>intellectual property</x></html> and how it applies to zinc finger proteins<br>
'''✓''' [https://2011.igem.org/Team:Harvard/Human_Practices Researched] <html><x>intellectual property</x></html> and how it applies to zinc finger proteins<br>
'''✓''' [https://2011.igem.org/Team:Harvard/Human_Practices Created] a <html><x>timeline and case study</x></html> of zinc finger intellectual property<br>
'''✓''' [https://2011.igem.org/Team:Harvard/Human_Practices Created] a <html><x>timeline and case study</x></html> of zinc finger intellectual property<br>

Revision as of 03:56, 29 October 2011

bar

Wiki Highlights

HARVshield logo.png
  • Read our project description and summary on our Project page: more details on how team members completed work for the three sections of our project are on Design, Synthesize, and Test pages, respectively.

Please be sure to stop by our poster during the poster session with any questions.

Accomplishments

Experimental Results

Researched zinc finger proteins and choose 6 novel, clinically relevant target sequences
Generated 55,000 zinc finger protein sequences using bioinformatics
Used three recently developed technologies together for the first time: a foundational advance
Expressed those 55,000 sequences in E.coli, with a sub-library for each target
Created a genomic one-hybrid selection system sensitive enough to detect one hit in a million
Found at least 15 novel zinc finger proteins

Biobricks and Protocols

Submitted 5 Biobricks to the registry, including our one-hybrid selection strain
Created several chassis for our Biobricks, including our one-hybrid selection strain
Used and shared our easy-to-follow protocols
Made protocols, Biobricks, and source code freely available, so that others can adapt them for other projects

Human Practices

[http://www.youtube.com/watch?feature=player_embedded&v=eBT8SaBAm80 Interviewed] zinc finger researchers Dr. Keith Joung and Dr. George Church
Interviewed chip-based DNA synthesis researcher Dr. Sri Kosuri Researched intellectual property and how it applies to zinc finger proteins
Created a timeline and case study of zinc finger intellectual property
Reached out to our elected representatives about the potential effects of IP on zinc finger research and synthetic biology generally
Handed out IP pamphlets and chassis data sheets at our poster presentation
Educated local high school students about synthetic biology to provide accurate information from sources other than the media.

Foundational Advance

Combining Computational Design, High-throughput Synthesis, and Selection

We brought together 3 new technologies to create a working pipeline that allows scientists to engineer novel protein-DNA interactions. Our methods represents a fundamentally different way of building new biological parts and devices: using selection to identify working members of a large computationally predicted library of potential designs.

Putting parts and devices directly onto the genome

The genome is the next frontier in synthetic biology. Our project has made use of genome modification in order to design a new device that allows the testing of DNA-protein interactions. We want iGEM and the broader synthetic biology community to use these techniques as an alternative to plasmids. To encourage their adoption, we have submitted new E. coli chassis that allow easy genome modification, and we have provided detailed protocols for their use.